STEGLUJAN
These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval: 2017
c2c553d8-5a9d-4366-bf53-8bdb5a876d19
HUMAN PRESCRIPTION DRUG LABEL
Oct 20, 2023
Merck Sharp & Dohme LLC
DUNS: 118446553
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
ertugliflozin and sitagliptin
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (15)
ertugliflozin and sitagliptin
Product Details
FDA regulatory identification and product classification information